Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.
Lenvatinib has been a very active agent both in the first-line setting and in patients previously treated with other agents, including ceritinib, says Brose.
In both cases, patients treated with lenvatinib are doing well and the response rate is very high. In a phase III trial, 63% of patients experienced a partial response, and a couple of complete responses were also reported.
Brose believes this is clinically significant, especially when patients have very aggressive or symptomatic disease.
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the SELECT trial, which looks at lenvatinib for patients with131I-refractory differentiated thyroid cancer.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More